BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allain JP, Hewitt PE, Tedder RS, Williamson LM. Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion. Br J Haematol. 1999;107:186-195. [PMID: 10520040 DOI: 10.1046/j.1365-2141.1999.01665.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 86] [Article Influence: 3.9] [Reference Citation Analysis]
Number Citing Articles
1 Yilmaz S, Unlu A, Cetinkaya RA, Yapar M, Avci IY, Yilmaz S, Eyigun CP. A strategical re-thinking on National Blood Donor Pool: Anti-HBc positivity related re-entry mechanisms. Transfus Apher Sci 2016;54:271-5. [PMID: 26928919 DOI: 10.1016/j.transci.2015.10.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
2 Mortensen E, Kamali A, Schirmer PL, Lucero-Obusan C, Winston CA, Oda G, Winters MA, Durfee J, Martinello RA, Davey VJ, Holodniy M. Are current screening protocols for chronic hepatitis B virus infection adequate? Diagn Microbiol Infect Dis 2016;85:159-67. [PMID: 27009896 DOI: 10.1016/j.diagmicrobio.2015.12.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
3 Allain JP, Cox L. Challenges in hepatitis B detection among blood donors. Curr Opin Hematol 2011;18:461-6. [PMID: 21912252 DOI: 10.1097/MOH.0b013e32834bac10] [Cited by in Crossref: 35] [Cited by in F6Publishing: 22] [Article Influence: 3.9] [Reference Citation Analysis]
4 Seed CR, Cheng A, Ismay SL, Bolton WV, Kiely P, Cobain TJ, Keller AJ; Virology Subcommittee of the National Donor and Product Safety Committee, Australian Red Cross Blood Service. Assessing the accuracy of three viral risk models in predicting the outcome of implementing HIV and HCV NAT donor screening in Australia and the implications for future HBV NAT. Transfusion 2002;42:1365-72. [DOI: 10.1046/j.1537-2995.2002.00204.x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 2.8] [Reference Citation Analysis]
5 Kupek E. Residual Risk of Hepatitis-B-Infected Blood Donations: Estimation Methods and Perspectives. ISRN Infectious Diseases 2013;2013:1-15. [DOI: 10.5402/2013/839896] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Kuhns MC, Busch MP. New Strategies for Blood Donor Screening for Hepatitis B Virus: Nucleic Acid Testing versus Immunoassay Methods. Mol Diag Ther 2006;10:77-91. [DOI: 10.1007/bf03256447] [Cited by in Crossref: 64] [Cited by in F6Publishing: 18] [Article Influence: 7.1] [Reference Citation Analysis]
7 Su TH, Chen PJ, Chen TC, Cheng HR, Li L, Lin KS, Kao JH, Chen DS, Liu CJ. The clinical significance of occult hepatitis B transfusion in Taiwan--a look-back study. Transfus Med. 2011;21:33-41. [PMID: 20726954 DOI: 10.1111/j.1365-3148.2010.01036.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
8 Gilson R, Brook MG. Hepatitis A, B, and C. Sex Transm Infect 2006;82 Suppl 4:iv35-9. [PMID: 17151052 DOI: 10.1136/sti.2006.023218] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
9 Urbani S, Fagnoni F, Missale G, Franchini M. The role of anti-core antibody response in the detection of occult hepatitis B virus infection. Clin Chem Lab Med. 2010;48:23-29. [PMID: 19919328 DOI: 10.1515/cclm.2010.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
10 Power JP, El Chaar M, Temple J, Thomas M, Spillane D, Candotti D, Allain JP. HBV reactivation after fludarabine chemotherapy identified on investigation of suspected transfusion-transmitted Hepatitis B virus. J Hepatol. 2010;53:780-787. [PMID: 20638744 DOI: 10.1016/j.jhep.2010.04.034] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
11 van Roosmalen MH, de Jong JJ, Haenen W, Jacobs T, Couwenberg F, Ahlers-de Boer GJ, Hellings JA. A new HBsAg screening assay designed for sensitive detection of HBsAg subtypes and variants. Intervirology 2006;49:127-32. [PMID: 16428888 DOI: 10.1159/000089373] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
12 Taira R, Satake M, Momose S, Hino S, Suzuki Y, Murokawa H, Uchida S, Tadokoro K. Residual risk of transfusion-transmitted hepatitis B virus (HBV) infection caused by blood components derived from donors with occult HBV infection in Japan. Transfusion. 2013;53:1393-1404. [PMID: 23033944 DOI: 10.1111/j.1537-2995.2012.03909.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
13 Alavian SM, Miri SM, Hollinger FB, Jazayeri SM. Occult Hepatitis B (OBH) in Clinical Settings. Hepat Mon 2012;12:e6126. [PMID: 23087749 DOI: 10.5812/hepatmon.6126] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
14 Ozkan S, Atak A, Bozdayi G, Turkcuoglu S, Maral I. Community-based research: cost of the tests used for anti-HBc total seropositivity only and hepatitis B screening. Transactions of the Royal Society of Tropical Medicine and Hygiene 2010;104:782-6. [DOI: 10.1016/j.trstmh.2010.08.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
15 Liu C, Chen D, Chen P. Epidemiology of HBV infection in Asian blood donors: Emphasis on occult HBV infection and the role of NAT. Journal of Clinical Virology 2006;36:S33-44. [DOI: 10.1016/s1386-6532(06)80007-7] [Cited by in Crossref: 72] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
16 Keyvani H, Agah S, Kabir A, Alavian S. Prevalence and risk factors of isolated anti-HBc antibody and occult hepatitis B infection in hemodialysis patients: a nationwide study. Annals of Hepatology 2013;12:213-9. [DOI: 10.1016/s1665-2681(19)31359-6] [Cited by in Crossref: 13] [Article Influence: 1.6] [Reference Citation Analysis]
17 Bhatti FA, Ullah Z, Salamat N, Ayub M, Ghani E. Anti-hepatits B core antigen testing, viral markers, and occult hepatitis B virus infection in Pakistani blood donors: implications for transfusion practice. Transfusion. 2007;47:74-79. [PMID: 17207233 DOI: 10.1111/j.1537-2995.2007.01066.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
18 Hennig H, Puchta I, Luhm J, Schlenke P, Goerg S, Kirchner H. Frequency and load of hepatitis B virus DNA in first-time blood donors with antibodies to hepatitis B core antigen. Blood. 2002;100:2637-2641. [PMID: 12239179 DOI: 10.1182/blood-2002-03-0798] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 4.2] [Reference Citation Analysis]
19 Allain J. Will genome detection replace serology in blood screening for microbial agents? Best Practice & Research Clinical Haematology 2000;13:615-29. [DOI: 10.1053/beha.2000.0103] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
20 Pandey P, Tiwari AK, Dara RC, Aggarwal G, Rawat G, Raina V. A comprehensive serological and supplemental evaluation of hepatitis B "seroyield" blood donors: A cross-sectional study from a tertiary healthcare center in India. Asian J Transfus Sci 2015;9:189-94. [PMID: 26420943 DOI: 10.4103/0973-6247.154252] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
21 Pereira A. Health and economic impact of posttransfusion hepatitis B and cost-effectiveness analysis of expanded HBV testing protocols of blood donors: a study focused on the European Union. Transfusion 2003;43:192-201. [DOI: 10.1046/j.1537-2995.2003.00280.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
22 Allain JP. Epidemiology of Hepatitis B virus and genotype. J Clin Virol. 2006;36 Suppl 1:S12-S17. [PMID: 16831687 DOI: 10.1016/s1386-6532(06)80003-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
23 Kleinman SH, Busch MP. HBV: amplified and back in the blood safety spotlight. Transfusion 2001;41:1081-5. [DOI: 10.1046/j.1537-2995.2001.41091081.x] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 3.0] [Reference Citation Analysis]
24 Satake M, Taira R, Yugi H, Hino S, Kanemitsu K, Ikeda H, Tadokoro K. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion. 2007;47:1197-1205. [PMID: 17581154 DOI: 10.1111/j.1537-2995.2007.01276.x] [Cited by in Crossref: 146] [Cited by in F6Publishing: 139] [Article Influence: 10.4] [Reference Citation Analysis]
25 Hoshi Y, Hasegawa T, Yamagishi N, Mizokami M, Sugiyama M, Matsubayashi K, Uchida S, Nagai T, Satake M. Optimal titer of anti-HBs in blood components derived from donors with anti-HBc. Transfusion 2019;59:2602-11. [PMID: 31168835 DOI: 10.1111/trf.15393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
26 Allain J. Occult hepatitis B virus infection. Transfusion Clinique et Biologique 2004;11:18-25. [DOI: 10.1016/j.tracli.2003.11.007] [Cited by in Crossref: 92] [Cited by in F6Publishing: 89] [Article Influence: 5.4] [Reference Citation Analysis]
27 Soldan K, Barbara JAJ, Dow BC. Transfusion-transmitted hepatitis B virus infection in the UK: a small and moving target: Recent cases of TT-HBV in the UK. Vox Sanguinis 2002;83:305-8. [DOI: 10.1046/j.1423-0410.2002.00228.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
28 Allain J. Occult hepatitis B virus infection and transfusion. Journal of Hepatology 2006;44:617-8. [DOI: 10.1016/j.jhep.2005.12.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
29 Brant LJ, Reynolds C, Byrne L, Davison KL. Hepatitis B and residual risk of infection in English and Welsh blood donors, 1996 through 2008. Transfusion 2011;51:1493-502. [PMID: 21470235 DOI: 10.1111/j.1537-2995.2011.03108.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
30 Yang Z, Xu L, Liu L, Feng Q, Zhang L, Ma W, Saldanha J, Wang M, Zhao L. Routine screening of blood donations at Qingdao central blood bank, China, for hepatitis B virus (HBV) DNA with a real-time, multiplex nucleic acid test for HBV, hepatitis C virus, and human immunodeficiency virus Types 1 and 2: NAT screening of blood donors in China. Transfusion 2013;53:2538-44. [DOI: 10.1111/trf.12159] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
31 Ye X, Li T, Xu X, Du P, Zeng J, Zhu W, Yang B, Li C, Allain JP. Characterisation and follow-up study of occult hepatitis B virus infection in anti-HBc-positive qualified blood donors in southern China. Blood Transfus 2017;15:6-12. [PMID: 27416568 DOI: 10.2450/2016.0268-15] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
32 Candotti D, Temple J, Owusu-Ofori S, Allain JP. Multiplex real-time quantitative RT-PCR assay for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1. J Virol Methods. 2004;118:39-47. [PMID: 15158067 DOI: 10.1016/j.jviromet.2004.01.017] [Cited by in Crossref: 68] [Cited by in F6Publishing: 67] [Article Influence: 4.0] [Reference Citation Analysis]
33 Seo DH, Whang DH, Song EY, Han KS. Occult hepatitis B virus infection and blood transfusion. World J Hepatol 2015;7:600-6. [PMID: 25848484 DOI: 10.4254/wjh.v7.i3.600] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
34 El-Zayadi AR, Ibrahim EH, Badran HM, Saeid A, Moneib NA, Shemis MA, Abdel-Sattar RM, Ahmady AM, El-Nakeeb A. Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission. Transfus Med. 2008;18:55-61. [PMID: 18279193 DOI: 10.1111/j.1365-3148.2007.00806.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
35 Pruss A, Caspari G, Krüger DH, Blümel J, Nübling CM, Gürtler L, Gerlich WH. Tissue donation and virus safety: more nucleic acid amplification testing is needed. Transpl Infect Dis. 2010;12:375-386. [PMID: 20412535 DOI: 10.1111/j.1399-3062.2010.00505.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
36 Stolz M, Tinguely C, Graziani M, Fontana S, Gowland P, Buser A, Michel M, Canellini G, Züger M, Schumacher P, Lelie N, Niederhauser C. Efficacy of individual nucleic acid amplification testing in reducing the risk of transfusion-transmitted hepatitis B virus infection in Switzerland, a low-endemic region. Transfusion 2010;50:2695-706. [PMID: 20573074 DOI: 10.1111/j.1537-2995.2010.02732.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
37 Romanò L, Velati C, Cambiè G, Fomiatti L, Galli C, Zanetti AR; SIMTI study group for HBV infection among first-time blood donors. Hepatitis B virus infection among first-time blood donors in Italy: prevalence and correlates between serological patterns and occult infection. Blood Transfus. 2013;11:281-288. [PMID: 23399361 DOI: 10.2450/2012.0160-12] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
38 Kuhns MC, Kleinman SH, Mcnamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy: HBsAg AND HBV DNA LEVELS IN HbsAg-POSITIVE, ANTI-HBc-REACTIVE BLOOD DONORS. Transfusion 2004;44:1332-9. [DOI: 10.1111/j.1537-2995.2004.04055.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 4.6] [Reference Citation Analysis]
39 Seed CR, Kiely P. A method for estimating the residual risk of transfusion-transmitted HBV infection associated with occult hepatitis B virus infection in a donor population without universal anti-HBc screening. Vox Sang 2013;105:290-8. [DOI: 10.1111/vox.12060] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
40 Dineva MA, Candotti D, Fletcher-Brown F, Allain JP, Lee H. Simultaneous visual detection of multiple viral amplicons by dipstick assay. J Clin Microbiol 2005;43:4015-21. [PMID: 16081944 DOI: 10.1128/JCM.43.8.4015-4021.2005] [Cited by in Crossref: 61] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
41 . Estimation of HBV transfusion risk. Transfusion 2009;49:1019-21. [DOI: 10.1111/j.1537-2995.2009.02122.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
42 Zeiler T, Karger R, Slonka J, Radsak K, Kretschmer V. Introducing Anti-HBc Screening in Germany – Possible Implications for the Blood Donation Service. Transfus Med Hemother 2006;33:453-8. [DOI: 10.1159/000094784] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
43 Weber B. Recent developments in the diagnosis and monitoring of HBV infection and role of the genetic variability of the S gene. Expert Rev Mol Diagn. 2005;5:75-91. [PMID: 15723594 DOI: 10.1586/14737159.5.1.75] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
44 Velati C, Fomiatti L, Baruffi L, Piccinini V, Prati D, Reina A, Lobbiani A, Zanetti A, Romanò L. Criteria for hepatitis B virus screening and validation of blood components in Italy: the position of the SIMTI HBV working group. Blood Transfus 2011;9:455-61. [PMID: 21839007 DOI: 10.2450/2011.0014-11] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
45 Allain JP, Candotti D. Diagnostic algorithm for HBV safe transfusion. Blood Transfus. 2009;7:174-182. [PMID: 19657480 DOI: 10.2450/2008.0062-08] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
46 O’Brien SF, Fearon MA, Yi QL, Fan W, Scalia V, Muntz IR, Vamvakas EC. Hepatitis B virus DNA-positive, hepatitis B surface antigen-negative blood donations intercepted by anti-hepatitis B core antigen testing: the Canadian Blood Services experience. Transfusion. 2007;47:1809-1815. [PMID: 17880605 DOI: 10.1111/j.1537-2995.2007.01396.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.7] [Reference Citation Analysis]
47 Hu K. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002;9:243-57. [DOI: 10.1046/j.1365-2893.2002.00344.x] [Cited by in Crossref: 204] [Cited by in F6Publishing: 198] [Article Influence: 10.7] [Reference Citation Analysis]
48 Harvala H, Reynolds C, Gibney Z, Derrick J, Ijaz S, Davison KL, Brailsford S. Hepatitis B infections among blood donors in England between 2009 and 2018: Is an occult hepatitis B infection a risk for blood safety? Transfusion 2021;61:2402-13. [PMID: 34114670 DOI: 10.1111/trf.16543] [Reference Citation Analysis]
49 Sood AK, Pangotra C, Manrai M. Prevalence of occult hepatitis B infection in patients visiting tertiary care hospital. Med J Armed Forces India 2016;72:140-4. [PMID: 27257324 DOI: 10.1016/j.mjafi.2016.02.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
50 Sacher RA, Schreiber GB, Kleinman SH. Prevention of transfusion-transmitted hepatitis. The Lancet 2000;355:331-2. [DOI: 10.1016/s0140-6736(99)00391-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
51 Bani-Sadr F, Maillard A, Ponscarme D, Scieux C, Molina JM. Reactivation of HBV replication in HIV-HBV infected patients. Am J Med 2003;114:768-9. [PMID: 12829207 DOI: 10.1016/s0002-9343(03)00156-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
52 Niederhauser C. Reducing the risk of hepatitis B virus transfusion-transmitted infection. J Blood Med 2011;2:91-102. [PMID: 22287868 DOI: 10.2147/JBM.S12899] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
53 Kaminski G, Alnaqdy A, Al-belushi I, Nograles J, Al-dhahry SH. Evidence of Occult Hepatitis B Virus Infection among Omani Blood Donors: A Preliminary Study. Med Princ Pract 2006;15:368-72. [DOI: 10.1159/000094271] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 0.7] [Reference Citation Analysis]
54 Chevrier MC, St-Louis M, Perreault J, Caron B, Castilloux C, Laroche J, Delage G. Detection and characterization of hepatitis B virus of anti-hepatitis B core antigen-reactive blood donors in Quebec with an in-house nucleic acid testing assay. Transfusion 2007;47:1794-802. [PMID: 17880603 DOI: 10.1111/j.1537-2995.2007.01394.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.3] [Reference Citation Analysis]
55 Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang. 2004;86:83-91. [PMID: 15023176 DOI: 10.1111/j.0042-9007.2004.00406.x] [Cited by in Crossref: 192] [Cited by in F6Publishing: 182] [Article Influence: 11.3] [Reference Citation Analysis]
56 Kleinman SH, Kuhns MC, Todd DS, Glynn SA, McNamara A, DiMarco A, Busch MP; Retrovirus Epidemiology Donor Study. Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening. Transfusion. 2003;43:696-704. [PMID: 12757519 DOI: 10.1046/j.1537-2995.2003.00391.x] [Cited by in Crossref: 131] [Cited by in F6Publishing: 130] [Article Influence: 7.3] [Reference Citation Analysis]
57 Kleinman S, Chan P, Robillard P. Risks associated with transfusion of cellular blood components in canada. Transfusion Medicine Reviews 2003;17:120-62. [DOI: 10.1053/tmrv.2003.50009] [Cited by in Crossref: 175] [Cited by in F6Publishing: 142] [Article Influence: 9.7] [Reference Citation Analysis]
58 Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol. 2009;51:798-809. [PMID: 19615780 DOI: 10.1016/j.jhep.2009.05.020] [Cited by in Crossref: 115] [Cited by in F6Publishing: 116] [Article Influence: 9.6] [Reference Citation Analysis]
59 Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion. 2008;48:1001-1026. [PMID: 18454738 DOI: 10.1111/j.1537-2995.2008.01701.x] [Cited by in Crossref: 119] [Cited by in F6Publishing: 108] [Article Influence: 9.2] [Reference Citation Analysis]
60 Sato S, Ohhashi W, Ihara H, Sakaya S, Kato T, Ikeda H. Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay. Transfusion 2001;41:1107-13. [DOI: 10.1046/j.1537-2995.2001.41091107.x] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 2.5] [Reference Citation Analysis]
61 Gutiérrez-García ML, Fernandez-Rodriguez CM, Lledo-Navarro JL, Buhigas-Garcia I. Prevalence of occult hepatitis B virus infection. World J Gastroenterol. 2011;17:1538-1542. [PMID: 21472117 DOI: 10.3748/wjg.v17.i12.1538] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
62 Howell DR, Webster MH, Barbara JAJ. Retrospective follow-up of recipients and donors of blood donations reactive for anti-HBc or for single HCV antibodies. Transfus Med 2000;10:265-9. [DOI: 10.1046/j.1365-3148.2000.00266.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.4] [Reference Citation Analysis]
63 Caspari G, Gerlich WH. Durch Blut übertragbare Infektionskrankheiten. In: Mueller-eckhardt C, Kiefel V, editors. Transfusionsmedizin. Berlin: Springer Berlin Heidelberg; 2004. pp. 599-645. [DOI: 10.1007/978-3-662-10597-9_36] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
64 Seed CR. Value of retaining HBsAg donor screening where HBV NAT and anti-HBc donor screening apply. VOXS 2018;13:70-5. [DOI: 10.1111/voxs.12368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
65 Christensen PB, Titlestad IL, Homburg KM, Georgsen J, Kristensen T. Hepatitis B core antibodies in Danish blood donors: a surrogate marker of risk behaviour: Hepatitis B core antibodies. Vox Sanguinis 2001;81:222-7. [DOI: 10.1046/j.0042-9007.2001.00113.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
66 Candotti D, El Chaar M, Allain J. Transfusion transmission of hepatitis B virus: still learning more about it: Transfusion transmission of hepatitis B virus. ISBT Science Series 2011;6:234-40. [DOI: 10.1111/j.1751-2824.2011.01493.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
67 Staginnus U, Corash L. Economics of Pathogen Inactivation Technology for Platelet Concentrates in Japan. International Journal of Hematology 2004;80:317-24. [DOI: 10.1532/ijh97.04131] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
68 Zeiler T, Karger R, Slonka J, Ketschmer V, Radsak K. Introduction of anti-HBc testing of blood donors in Germany. Transfus Med 2006;16:441-3. [DOI: 10.1111/j.1365-3148.2006.00685.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
69 Juhl D, Luhm J, Görg S, Ziemann M, Hennig H. Evaluation of algorithms for the diagnostic assessment and the reentry of blood donors who tested reactive for antibodies against hepatitis B core antigen: ANTI-HBc TESTING OF BLOOD DONORS. Transfusion 2011;51:1477-85. [DOI: 10.1111/j.1537-2995.2010.03031.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
70 Durro V, Qyra S. Trends in prevalence of hepatitis B virus infection among Albanian blood donors, 1999-2009. Virol J 2011;8:96. [PMID: 21375724 DOI: 10.1186/1743-422X-8-96] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
71 Brook MG. European guideline for the management of hepatitis B and C virus infections. Int J STD AIDS 2001;12:48-57. [DOI: 10.1258/0956462011923930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
72 Kleinman S, Vamvakas EC. Assessment of the Risk of Transfusion-Transmitted Viral Infections. Transfus Alternat Transfus Med 2003;5:319-25. [DOI: 10.1111/j.1778-428x.2003.tb00169.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
73 Liu CJ, Lo SC, Kao JH, Tseng PT, Lai MY, Ni YH, Yeh SH, Chen PJ, Chen DS. Transmission of occult hepatitis B virus by transfusion to adult and pediatric recipients in Taiwan. J Hepatol. 2006;44:39-46. [PMID: 16168517 DOI: 10.1016/j.jhep.2005.06.016] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 5.1] [Reference Citation Analysis]
74 Larrubia JR. Occult hepatitis B virus infection: a complex entity with relevant clinical implications. World J Gastroenterol. 2011;17:1529-1530. [PMID: 21472115 DOI: 10.3748/wjg.v17.i12] [Reference Citation Analysis]
75 Bhattacharya P, Chandra PK, Datta S, Banerjee A, Chakraborty S, Rajendran K, Basu SK, Bhattacharya SK, Chakravarty R. Significant increase in HBV, HCV, HIV and syphilis infections among blood donors in West Bengal, Eastern India 2004-2005: exploratory screening reveals high frequency of occult HBV infection. World J Gastroenterol. 2007;13:3730-3733. [PMID: 17659734 DOI: 10.3748/wjg.v13.i27.3730] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.1] [Reference Citation Analysis]
76 Allain JP, Candotti D, Soldan K, Sarkodie F, Phelps B, Giachetti C, Shyamala V, Yeboah F, Anokwa M, Owusu-Ofori S. The risk of hepatitis B virus infection by transfusion in Kumasi, Ghana. Blood. 2003;101:2419-2425. [PMID: 12393691 DOI: 10.1182/blood-2002-04-1084] [Cited by in Crossref: 106] [Cited by in F6Publishing: 103] [Article Influence: 5.6] [Reference Citation Analysis]
77 Yang MH, Li L, Hung YS, Hung CS, Allain JP, Lin KS, Tsai SJ. The efficacy of individual-donation and minipool testing to detect low-level hepatitis B virus DNA in Taiwan. Transfusion. 2010;50:65-74. [PMID: 19709394 DOI: 10.1111/j.1537-2995.2009.02357.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
78 Owusu-Ofori S, Temple J, Sarkodie F, Anokwa M, Candotti D, Allain JP. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings. Transfusion 2005;45:133-40. [PMID: 15660820 DOI: 10.1111/j.1537-2995.2004.04279.x] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 6.0] [Reference Citation Analysis]
79 Soldan K, Gay N, Allain J, Llewelyn C, Jones C, Reeves I, Ramsay M. The Prevalence of Hepatitis B Infection in Adults with no Recognized Increased Risk of Infection. Journal of Infection 2000;41:198-9. [DOI: 10.1053/jinf.2000.0722] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
80 Altunay H, Kosan E, Birinci I, Aksoy A, Kirali K, Saribas S, Aslan M, Yuksel P, Alan E, Yenen OS, Kocazeybek B. Are isolated anti-HBc blood donors in high risk group? The detection of HBV DNA in isolated anti-HBc cases with nucleic acid amplification test (NAT) based on transcription-mediated amplification (TMA) and HBV discrimination. Transfusion and Apheresis Science 2010;43:265-8. [DOI: 10.1016/j.transci.2010.09.012] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
81 Mühlbacher A, Zdunek D, Melchior W, Michl U. Is infective blood donation missed without screening for antibody to hepatitis B core antigen and/or hepatitis B virus DNA?: Letters. Vox Sanguinis 2001;81:139-139. [DOI: 10.1046/j.1423-0410.2001.00086.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
82 Ahmad AE, Bakari AG, Musa BOP, Mustapha SK, Jamoh BY, Abdullahi IN, Tahir MI, Olatunji AO, Maishanu SH, Suleiman AB, Tolulope A, Hawkins C, Sagay AS, Zoakah A, Olayinka AT. Pattern of prevalent Hepatitis B virus genotypes in Zaria, Nigeria. Niger Postgrad Med J 2019;26:80-6. [PMID: 31187746 DOI: 10.4103/npmj.npmj_59_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
83 Schmidt M, Nübling CM, Scheiblauer H, Chudy M, Walch LA, Seifried E, Roth WK, Hourfar MK. Anti-HBc screening of blood donors: a comparison of nine anti-HBc tests. Vox Sang. 2006;91:237-243. [PMID: 16958836 DOI: 10.1111/j.1423-0410.2006.00818.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 43] [Article Influence: 2.7] [Reference Citation Analysis]
84 Wendel S. Rational testing for transmissible diseases. ISBT Science Series 2007;2:19-24. [DOI: 10.1111/j.1751-2824.2007.00098.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
85 Masarone M, De Renzo A, La Mura V, Sasso FC, Romano M, Signoriello G, Rosato V, Perna F, Pane F, Persico M. Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma. BMC Gastroenterol 2014;14:31. [PMID: 24533834 DOI: 10.1186/1471-230X-14-31] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
86 Busch MP. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfusion Clinique et Biologique 2004;11:26-32. [DOI: 10.1016/j.tracli.2003.12.003] [Cited by in Crossref: 63] [Cited by in F6Publishing: 62] [Article Influence: 3.7] [Reference Citation Analysis]